(Q37798577)

23 August 2017

Translational research in oncology: key bottlenecks and new paradigms (English)

1 reference

23 August 2017

Richard Simon

1

1 reference

23 August 2017

7 October 2010

1 reference

Expert Reviews in Molecular Medicine

23 August 2017

1 reference

23 August 2017

12

1 reference

23 August 2017

e32

1 reference

Mutation and cancer: statistical study of retinoblastoma

23 August 2017

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

Shifting paradigms: the seeds of oncogene addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

Clinical trial design for microarray predictive marker discovery and assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

Randomized clinical trials with biomarkers: design issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

Attacking cancer at its foundation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

Clinical trial designs for predictive biomarker validation: one size does not fit all.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

Perspectives on the development of imatinib and the future of cancer research

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

US biomedical research: basic, translational, and clinical sciences

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

Clinical trial designs for predictive marker validation in cancer treatment trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

Translational Medicine: A two-way road

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

The Translational Research Working Group developmental pathways: introduction and overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

The use of genomics in clinical trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

Central Challenges Facing the National Clinical Research Enterprise

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

Clinical trial designs for prospective validation of biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

Randomized phase III clinical trial designs for targeted agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

Declining death rates reflect progress against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

Pharmacogenomic predictor discovery in phase II clinical trials for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

The cancer biomarker problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

Genetic progression and the waiting time to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

A two-stage theory of carcinogenesis in relation to the age distribution of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

On the dynamics of breast tumor development in women carrying germline BRCA1 and BRCA2 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

Estimating the number of rate limiting genomic changes for human breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

Carcinogenesis modeling: from molecular biology to epidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

Use of archived specimens in evaluation of prognostic and predictive biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

Effective incorporation of biomarkers into phase II trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

Selection, the mutation rate and cancer: Ensuring that the tail does not wag the dog

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

The cross-validated adaptive signature design

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

7 January 2021

Designs and adaptive analysis plans for pivotal clinical trials of therapeutics and companion diagnostics

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

7 January 2021

Evaluating the efficiency of targeted designs for randomized clinical trials

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

7 January 2021

Clinical trials for predictive medicine: new challenges and paradigms

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

7 January 2021

On the efficiency of targeted clinical trials

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

7 January 2021

Perspectives and challenges of clinical pharmacogenomics in cancer

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

7 January 2021

The National Institutes of Health and clinical research: a progress report

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

7 January 2021

Translational research: are we on the right track? 2008 American Society for Clinical Investigation Presidential Address

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

7 January 2021

Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients

1 reference

https://api.crossref.org/works/10.1017%2FS1462399410001638

7 January 2021

10.1017/S1462399410001638

Identifiers

DOI

1 reference

release_rdbzogzpmfgclifsxlp5ycsc3q

23 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/rdbzogzpmfgclifsxlp5ycsc3q

24 November 2022

mapped directly with Wikidata item

PubMed ID

20929594

1 reference

PubMed ID

20929594